Troriluzole hydrochloride is under clinical development by Biohaven and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase III drugs for Recurrent Glioblastoma Multiforme (GBM) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Troriluzole hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Troriluzole hydrochloride overview
Troriluzole Hydrocholride (trigriluzole, BHV-4157) is under development for the treatment of spinocerebellar ataxia, obsessive-compulsive disorder, recurrent glioblastoma multiforme and gliosarcoma. The drug candidate targets glutamate neurotransmitter. It is administered through oral route. It is a new chemical entity and a prodrug of riluzole (BHV-0223).
It was under development for the treatment of neuropsychiatric disorders, generalized anxiety disorder, Friedreich Ataxia, metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, bladder cancer, classic Hodgkin lymphoma and Alzheimer's disease.
Biohaven overview
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of Troriluzole hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
